Susceptibility Pattern and Epidemiology of Mycobacterium tuberculosis in United Emirati Hospital.
OBJECTIVE
Human tuberculosis (TB) has re-emerged at an alarming rate as one of the deadliest contagious diseases; not only in the developing world, but also in the developed countries. Its re-emergence indicates failure to control its transmission. What causes part of the alarm is the growing number of isolates displaying resistance to the first line drugs used in its control. The very high volume of travel to the United Arab Emirates (UAE) is yet another reason for concern over the spread of the disease. This study reports on the pattern of multiple drug (MDR) resistance exhibited by Mycobacterium tuberculosis (MTB) isolates from a major hospital in the UAE.


METHODS
All pulmonary and extrapulmonary tuberculosis patients with positive culture results from January 2001 to December 2008 were included in the study. Cultures were performed at the mycobacteriology laboratory of the Emirati Hospital, Abu Dhabi, UAE, using the conventional Lewes-Johnson media. M. tuberculosis was isolated by standard procedures. M. tuberculosis complex was identified by conventional biochemical tests. Anti-mycobacterial sensitivity testing was done by the disk method as described by Wayne & Krasnow.


RESULTS
From 2002 to 2008, 43 nonrepetitive culture-positive cases were identified. The resistance rates of M. tuberculosis to tested first-line agents were as follows: isoniazid, 34.5%; pyrazinamide, 34.8%; rifampin, 32.5%; streptomycin, 25.6%; and ethambutol, 20.9%. The resistance rate to isoniazid, rifampin and pyrazinamide was 7%; to isoniazid, rifampin and streptomycin was 2.3%; and to isoniazid, rifampin, streptomycin and pyrazinamide was 2.3%. The resistance rate to all the five agents together was 4.6%.


CONCLUSIONS
This study is the first in the UAE to report such high levels of resistance to anti-TB drugs; 27.7% for anti-tuberculosis Drugs such as isoniazid and pyrazinamide are of great significance to achieve proper treatment in M. tuberculosis infections in future. Indeed, isoniazid and rifampicin are important components of any regimen for the treatment of drug susceptible TB.
Saif Alfaresi
Mubarak
M
Department of Pathology & Laboratory Medicine, Zayed Military Hospital, Abu Dhabi, UAE.
Hag-Ali
Mohammed
M
Saudi Med J. 1998 Mar;19(2):212-214
27701594
Tubercle. 1991 Mar;72(1):51-5
1909061
Indian J Med Res. 2005 Apr;121(4):235-9
15817941
Tubercle. 1989 Sep;70(3):207-10
2515647
Saudi Med J. 1999 Dec;20(12):927-30
27644713
N Engl J Med. 2001 Apr 26;344(17):1294-303
11320389
Tuberculosis (Edinb). 2003;83(1-3):44-51
12758188
MMWR Morb Mortal Wkly Rep. 2004 Mar 19;53(10):209-14
15029114
Saudi Med J. 2006 Sep;27(9):1346-51
16951771
Int J Antimicrob Agents. 2001 May;17(5):415-8
11337231
JAMA. 1995 Jan 18;273(3):220-6
7807661
JAMA. 1994 Mar 2;271(9):665-71
8080502
Am J Clin Pathol. 1966 Jun;45(6):769-71
4956595
Lancet. 1997 Aug 30;350(9078):624-9
9288045
JAMA. 1994 Aug 17;272(7):535-9
8046808